Sage Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $25 Price Target
SAGE Therapeutics: A Balanced Hold Rating Amidst Promising Zurzuvae Launch and Clinical Pipeline Prospects
Sage Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $23
Sage Therapeutics Analyst Ratings
Sage Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $25 Price Target
Sage Therapeutics Analyst Ratings
Baird Maintains Neutral on Sage Therapeutics, Maintains $15 Price Target
Sell Rating on SAGE Therapeutics Amid Concerns Over Zurzuvae's Market Adoption and Safety Profile
Baird Initiates Sage Therapeutics With Neutral Rating, $15 Price Target
Sage Therapeutics Analyst Ratings
Sage Therapeutics Inc: Baird Starts Insurance with Neutral Rating and $15 Target
Sell Rating on SAGE Therapeutics Amidst High Risk and Uncertain Pipeline Success
Sage Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $28
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and SAGE Therapeutics (SAGE)
Goldman Sachs: Maintaining the Sage Therapeutics (SAGE.US) rating, adjusted from neutral to neutral, and adjusted the target price from $28.00 to $19.00.
Sage Therapeutics Analyst Ratings